SLC5A2 and chronic kidney disease: The results suggest that effective control of both hyperglycemia and blood pressure with combined treatment with SGLT2 and ACE inhibitors is an attractive therapeutic option for treatment of both type 1 and 2 diabetes that can slow the development and progression of CKD.